Globe Newswire (Wed, 10-Jun 7:30 AM ET)
Globe Newswire (Sat, 6-Jun 5:15 AM ET)
Globe Newswire (Tue, 26-May 7:00 AM ET)
Globe Newswire (Tue, 19-May 7:00 AM ET)
Globe Newswire (Mon, 18-May 5:00 PM ET)
Business Wire (Mon, 18-May 8:34 AM ET)
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
Globe Newswire (Thu, 7-May 7:00 AM ET)
Business Wire (Tue, 28-Apr 7:00 AM ET)
Market Chameleon (Tue, 10-Mar 5:19 AM ET)
Market Chameleon (Mon, 1-Dec 4:04 AM ET)
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Cullinan Therapeutics trades on the NASDAQ stock market under the symbol CGEM.
As of July 7, 2026, CGEM stock price climbed to $18.36 with 286,423 million shares trading.
CGEM has a beta of 1.04, meaning it tends to be more sensitive to market movements. CGEM has a correlation of 0.03 to the broad based SPY ETF.
CGEM has a market cap of $1.13 billion. This is considered a Small Cap stock.
Last quarter Cullinan Therapeutics reported $0 in Revenue and -$.75 earnings per share. This fell short of revenue expectation by $-3 million and exceeded earnings estimates by $.09.
In the last 3 years, CGEM traded as high as $30.19 and as low as $5.68.
The top ETF exchange traded funds that CGEM belongs to (by Net Assets): XBI, VTI, IWM, IWN, VXF.
CGEM has outperformed the market in the last year with a price return of +135.1% while the SPY ETF gained +21.0%. CGEM has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +23.1% and +6.1%, respectively, while the SPY returned +14.0% and +0.6%, respectively.
CGEM support price is $16.80 and resistance is $18.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CGEM shares will trade within this expected range on the day.
